Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Corvas, Pfizer deal

Pfizer exercised its option to enter into an exclusive license

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE